Stoke Therapeutics (STOK) Stock Price, News & Analysis

Company Overview

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy. In addition to STK-001, Stoke is advancing STK-002, its preclinical candidate for spinocerebellar ataxia type 6 (SCA6), along with other discovery-stage programs targeting genetic diseases characterized by insufficient protein levels. Stoke’s approach aims to address the underlying genetic deficiency rather than solely treating symptoms, positioning its pipeline to potentially benefit a range of patient populations with high unmet medical needs.

Since going public on the Nasdaq exchange in early 2020, Stoke Therapeutics has grown its research capabilities and established strategic collaborations to support its development efforts. The company’s leadership team brings together expertise in molecular biology, neurology and clinical development, guiding Stoke’s mission to translate its TANGO platform into transformative therapies. Stoke serves patient communities and clinical partners globally, with ongoing and planned trials conducted across North America and Europe.

Key Stats

• Today's Range: $24.61 to $25.61
• 50-Day Range: $12.50 to $25.56
• 52-Week Range: $5.35 to $25.61
• Volume: 749,189 shs
• Average Volume: 1.05 million shs
• Market Capitalization: $1.40 billion
• P/E Ratio: 30.07
• Dividend Yield: N/A
• Price Target: $25.57
• Consensus Rating: Buy

Stoke Therapeutics Stock Analysis - MarketRank™

Stoke Therapeutics scored higher than 54% of companies evaluated by MarketBeat, and ranked 523rd out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.5 / 5
• Analyst Rating: Buy

Consensus Rating

Stoke Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and 1 sell rating.

Upside/Downside

The consensus price target for Stoke Therapeutics is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Stoke Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Stoke Therapeutics are expected to decrease in the coming year, from ($2.01) to ($2.27) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Stoke Therapeutics is 30.07, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 284.00.

Price to Earnings Ratio vs. Sector

The P/E ratio of Stoke Therapeutics is 30.07, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 77.33.

Price to Book Value per Share Ratio

Stoke Therapeutics has a P/B Ratio of 5.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

20.79% of the outstanding shares of Stoke Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Stoke Therapeutics has a short interest ratio ("days to cover") of 13.1, which indicates bearish sentiment.

Change versus previous month

Short interest in Stoke Therapeutics has recently increased by 6.05%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Stoke Therapeutics does not currently pay a dividend.

Dividend Growth

Stoke Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.8 / 5
• Environmental Score: -0.59

Percentage of Shares Shorted

20.79% of the outstanding shares of Stoke Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Stoke Therapeutics has a short interest ratio ("days to cover") of 13.1, which indicates bearish sentiment.

Change versus previous month

Short interest in Stoke Therapeutics has recently increased by 6.05%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Stoke Therapeutics this week, compared to 6 articles on an average week.

Search Interest

23 people have searched for STOK on MarketBeat in the last 30 days. This is an increase of 15% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Stoke Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Stoke Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,063,359.00 in company stock.

Percentage Held by Insiders

Only 9.50% of the stock of Stoke Therapeutics is held by insiders.

STOK Stock Analysis - Frequently Asked Questions

How have STOK shares performed this year?

Stoke Therapeutics' stock was trading at $11.03 at the beginning of the year. Since then, STOK stock has increased by 131.7% and is now trading at $25.56.

How were Stoke Therapeutics' earnings last quarter?

Stoke Therapeutics, Inc. (NASDAQ:STOK) announced its quarterly earnings results on Tuesday, August, 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.17. The company had revenue of $13.82 million for the quarter, compared to analysts' expectations of $31.51 million. Stoke Therapeutics had a net margin of 26.25% and a trailing twelve-month return on equity of 18.32%.
Read the conference call transcript.

When did Stoke Therapeutics IPO?

Stoke Therapeutics (STOK) raised $100 million in an IPO on Wednesday, June 19th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

How do I buy shares of Stoke Therapeutics?

Shares of STOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Stoke Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Stoke Therapeutics investors own include Enovix (ENVX), Rambus (RMBS), COMPASS Pathways (CMPS), Globant (GLOB), Ginkgo Bioworks (DNA), Toast (TOST) and Saia (SAIA).

Company Calendar

• Last Earnings: 8/12/2025
• Today: 10/03/2025
• Next Earnings (Estimated): 11/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:STOK
• CIK: 1623526
• Web: www.stoketherapeutics.com
• Phone: (781) 430-8200
• Fax: N/A
• Employees: 100
• Year Founded: 2014

Price Target and Rating

• Average Price Target for Stoke Therapeutics: $25.57
• High Price Target: $35.00
• Low Price Target: $18.00
• Potential Upside/Downside: +0.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.85
• Trailing P/E Ratio: 30.07
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$88.98 million
• Net Margins: 26.25%
• Pretax Margin: 26.90%
• Return on Equity: 18.32%
• Return on Assets: 15.48%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.98
• Quick Ratio: 6.98

Sales & Book Value

• Annual Sales: $36.56 million
• Price / Sales: 38.31
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.32 per share
• Price / Book: 5.92

Miscellaneous

• Outstanding Shares: 54,800,000
• Free Float: 49,591,000
• Market Cap: $1.40 billion
• Optionable: Optionable
• Beta: 1.24